Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial

Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial

This study aims to assess the efficacy and safety of using combination of 755-nm picosecond alexandrite laser and 2% hydroquinone compared with 2% hydroquinone alone for the treatment of melasma: A randomized split-face controlled trial

Inclusion Criteria:

• Both male and female age 18-60 years
• Melasma on both cheeks - epidermal or mixed type
• Fitzpatrick Skin type III-V

Exclusion Criteria:

• History of retinoid or other keratolytic drugs used within 6 months before enrolled
• History of keloid
• photosensitivity
• Immunocompromised host